Care & Cure

Based on ARS Original Technology Company

CureBio

is a Biopharmaceutical Company developing
new peptide drug of cancer and dermatology

Based on ARS original technology platform to develop new drug in Asia’s first company

  • New technology from ARS-derived peptides
  • Diseases including cancer and new drug development
  • Pipeline is a first-in-class drug
  • Concept is similar immunotherapeutic drugs

Our vision is the guardian of life and
mission is

Care & Cure

Core technology :
ARS are therapeutic targets

“The emerging biology and therapeutic applications of human ARSs in diseases including autoimmune and rare diseases, and cancer”

Nature reviews drug discovery 18 : 629-650 (2019)

ARSs :
disease associations

Under stress condition,
ARSs are linked to many diseases
: Focused on GRS and AIMP1

PNAS 32 : 11043-11049 (2008)

Publications

Reviews
Biocon’s target factory
Nature Biotechnology. Volume 36 Number 9. September 2018.
Extracellular activities of aminoacyl-tRNA synthetase: new mediators for cell-cell communication.
Top Curr Chem. 344:145-166.
Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping.
Nat Rev Cancer. 2011. 11:708-18.
A tipping point for mistranslation and disease.
Nat Struct Mol Bio. 2009. 15:348-9.
Aminoacyl-tRNA synthetase and their connections to disease.
Proc Natl Acad Sci USA. 2008. 105:11043-9.
Associated Disease Research
Secreted tryptophanyl-tRNA synthetase as a primary defense system against infection.
Nat Microbiol. 2016. 2:16191.
ARS-interacting multi-functional protein induces proliferation of human bone marrow-derived mesenchymal stem cells by accumulation of b-catenin via fibroblast growth factor receptor 2-mediated activation of Akt.
Stem Cells Dev. 2013. 22:2630-40.
Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis.
Proc Natl Acad Sci USA. 2012. 109:E640-7.

Patents

0
International
0
Domestic
Registered Patent
Composition for preventing and treating inflammatory diseases comprising inhibitor of AIMP2-DX2 as an active ingredient.
10-1067816
Functional sitting mat using brain wave.
20-0463994
Remote control device for electronic devices using brain wave and image device.
10-1077661
NOVEL PEPTIDE AND USE THEREOF.
10-1020658
NOVEL PEPTIDE AND USE THEREOF.
5002603
Novel peptide and uses thereof.
CN101370821
Novel fragments of the AIMP1 protein and composition for promoting hair growth comprising thereof.
10-2017796
Novel fragments of the AIMP1 protein and composition for promoting hair growth comprising thereof.
10-2024055
Topical Pharmaceutical Composition and cosmetic composition comprising the extract of complex herb an active ingredient for preventing and alleviating allergic or non-allergic skin disease.
10-1189938
Pharmaceutical Composition and heath care food comprising the extract of complex herb an active ingredient for preventing and treating allergic or non-allergic skin disease.
10-1231446
Patent Application
NOVEL AIMP1 PROTEIN FRAGMENT AND HAIR GROWTH-PROMOTING COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT.
16/320,404
NOVEL AIMP1 PROTEIN FRAGMENT AND HAIR GROWTH-PROMOTING COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT.
2019-527105
NOVEL AIMP1 PROTEIN FRAGMENT AND HAIR GROWTH-PROMOTING COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT.
17 834780.3
NOVEL AIMP1 PROTEIN FRAGMENT AND HAIR GROWTH-PROMOTING COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT.
201780058118.1
Fragmented GRS polypeptide, mutants thereof and use thereof.
10-2018-0058647

R&D Pipeline

Currently CureBio has three defined development projects, all based on our research on human proteins. Our two drug candidates, NeoPep GT and NeoPep A1H are small peptides. Glycyl-tRNA synthetase (GRS)-derived peptides (NeoPep GT) are a series of anti-tumorigenic peptides derived from the natural immune-surveillance agent, GRS. ARS-interacting multifunctional protein 1 (AIMP1)-derived peptides (NeoPep A1H) comprise a hair growth peptide derived from the natural anti-aging agent, AIMP1. The profile of each drug candidate is described in short in the following diagram.

NeoPep GT

  • Drug Candidate : GRS-derived peptide
  • Indication : Renal Cell Carcinoma
  • Development state : 2020 1q Pre-clinical

NeoPep A1H

  • Drug Candidate : AIMP1-derived peptide
  • Indication : Dermatology/ Alopecia
  • Development state : 2019 4Q Pre-clinical

NeoPep GT

  • Drug Candidate : GRS-derived peptide
  • Indication : Ovarian Cancer
  • Development state : 2019 Optimization of lead

CURE BIO Co., Ltd.

Marketing Headquarters

  • Hangang City Life, 834 Olympic-ro, Gangdong-gu, Seoul, 05238 Korea
  • T. +82-2-427-3669
  • F. +82-2-6280-0257
  • E. curebio@curebio.co.kr

Research Headquarters

  • 9fl, B-dong, 145 Gwanggyo-ro, Yeongtong-gu, Suwon-si, Gyeonggi-do, 16229 Korea
  • T. +82-31-888-9933
  • F. +82-31-888-9954
  • E. cure-bio@curebio.co.kr